Abstract:Disease-associated mutations endow SHP2 liquid-liquid phase separation capabilitySHP2 LLPS is driven by electrostatic interactions mediated by PTP domainSHP2 allosteric inhibitors block SHP2 LLPS by locking SHP2 in closed conformationMutant SHP2 can recruit and activate WT SHP2 in LLPS to promote MAPK activationThe non-receptor protein tyrosine phosphatase (PTP) SHP2, encoded by PTPN11, plays an essential role in RAS-mitogen-activated protein kinase (MAPK) signaling during normal development. It has been perplexing as to why both enzymatically activating and inactivating mutations in PTPN11 result in human developmental disorders with overlapping clinical manifestations. Here, we uncover a common liquid-liquid phase separation (LLPS) behavior shared by these disease-associated SHP2 mutants. SHP2 LLPS is mediated by the conserved well-folded PTP domain through multivalent electrostatic interactions and regulated by an intrinsic autoinhibitory mechanism through conformational changes. SHP2 allosteric inhibitors can attenuate LLPS of SHP2 mutants, which boosts SHP2 PTP activity. Moreover, disease-associated SHP2 mutants can recruit and activate wild-type (WT) SHP2 in LLPS to promote MAPK activation. These results not only suggest that LLPS serves as a gain-of-function mechanism involved in the pathogenesis of SHP2-associated human diseases but also provide evidence that PTP may be regulated by LLPS that can be therapeutically targeted.<ol class="links-for-figure"><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420311430-fx1_lrg.jpg">Download : Download high-res image (167KB)</a></li><li><a class="anchor download-link u-font-sans" href="https://ars.els-cdn.com/content/image/1-s2.0-S0092867420311430-fx1.jpg">Download : Download full-size image</a></li></ol>

Catalytically inactive SHP1-C453S mutant gain of “robust LLPS” function

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation

A novel partially open state of SHP2 points to a “multiple gear” regulation mechanism

The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain

Structural and biochemical characterization of active sites mutant in human inorganic pyrophosphatase

Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study

Study of SHP-2 (PTPN11) Allosterism on Structural Movement Using Solution Perturbed Molecular Dynamics Simulation

Conditional Deletion Of Shp2 Tyrosine Phosphatase In Thymocytes Suppresses Both Pre-Tcr And Tcr Signals

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved "backdoor" cysteine

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity

SHP-1 Variants Broaden the Understanding of pH-Dependent Activities in Protein Tyrosine Phosphatases

Time-resolved phosphoproteomics reveals scaffolding and catalysis-responsive patterns of SHP2-dependent signaling

Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state

Identification of Shp-2 as a Stat5A Phosphatase

Phosphatase-independent Functions of SHP2 and Its Regulation by Small Molecule Compounds.

Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy

Single Ion Pair Is Essential for Stabilizing SHP2's Open Conformation

Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds

SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis